Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Lorbrena (lorlatinib) CROWN study shows majority of patients with ALK-positive advanced lung cancer living beyond five years without disease progression – Pfizer

Written by | 15 Jun 2024

Pfizer Inc. announced longer-term follow-up results from the Phase III CROWN trial evaluating Lorbrena (lorlatinib, a third-generation ALK inhibitor, available in Europe under the brand name Lorviqua) versus… read more.

Tagrisso (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial – AstraZeneca

Written by | 13 Jun 2024

Positive results from the LAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with… read more.

Study: Access to targeted lung cancer drug is cost-prohibitive globally

Written by | 5 Jun 2024

Many countries with national healthcare systems or payers such as insurance companies use cost-effectiveness analyses to decide whether to cover new medicines, balancing treatment costs with potential health… read more.

Approval of Augtyro (repotrectinib) for patients with ROS1-positive NSCLC by China’s NMPA – Zai Lab

Written by | 26 May 2024

Zai Lab Limited announced that the National Medical Products Administration (NMPA) in China has approved the New Drug Application (NDA) for Augtyro (repotrectinib) for the treatment of adult… read more.

FDA approves Imdelltra (taralatamab-dlle),the first and only T cell engager therapy to treatextensive stage small cell lung cancer – Amgen

Written by | 24 May 2024

Amgen announced that the FDA has approved Imdelltra (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after… read more.

Perioperative nivolumab shows significant efficacy in lung cancer treatment

Written by | 18 May 2024

When compared with pre-surgical (neoadjuvant) chemotherapy only, adding perioperative immunotherapy before and after surgery significantly improves event-free survival in patients with resectable early-stage non-small cell lung cancer (NSCLC),… read more.

Phase III CheckMate-73L trial did not meet its primary endpoint in stage III non-small cell lung cancer – BMS

Written by | 17 May 2024

Bristol Myers Squibb announced the Phase III CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell… read more.

European Commission approval for tislelizumab as treatment for non-small cell lung cancer – BeiGene

Written by | 28 Apr 2024

BeiGene, Ltd. announced that the European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use…. read more.

FDA approves Alecensa (alectinib) as the first adjuvant treatment for people with ALK-positive early-stage lung cancer – Genentech/Roche

Written by | 23 Apr 2024

Roche announced that the FDA has approved Alecensa (alectinib) for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours… read more.

European Commission approves Keytruda (pembrolizumab) + chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer at high risk of recurrence in adults – Merck

Written by | 15 Apr 2024

Merck Inc., known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved Keytruda, Merck’s anti-PD-1 therapy, in combination with platinum-containing… read more.

Abecma (idecabtagene vicleucel) becomes first CAR T Cell therapy approved in the European Union in earlier lines for triple-class exposed relapsed and refractory multiple myeloma – BMS

Written by | 25 Mar 2024

Bristol Myers Squibb announced that the European Commission (EC) has granted approval to Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and refractory multiple… read more.

Improving access to early-stage lung cancer care in Europe

Written by | 8 Mar 2024

There are stark differences between European countries when it comes to both the reimbursement of, and access to, new treatments for patients with early-stage lung cancer. There are… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.